Comparative Pharmacology
Head-to-head clinical analysis: BLISOVI FE 1 5 30 versus FEMLYV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLISOVI FE 1 5 30 versus FEMLYV.
BLISOVI FE 1.5/30 vs FEMLYV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Blisovi Fe 1.5/30 is a combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone (progestin). It inhibits ovulation via suppression of gonadotropins (FSH and LH). Additionally, it increases cervical mucus viscosity, impeding sperm penetration, and alters endometrial development, reducing implantation likelihood.
Combination of levonorgestrel, a progestin, and ethinyl estradiol, an estrogen; suppresses gonadotropins, inhibits ovulation, alters cervical mucus and endometrium.
One tablet orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets (iron-free).
FEMLYV (norethindrone acetate/ethinyl estradiol) is administered as one tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo tablets. The dosing regimen is continuous cyclic.
None Documented
None Documented
Ethinyl estradiol: terminal half-life ~17 hours (range 13–27 h) with single dose; for norethindrone: ~8–11 hours. Clinical context: Steady-state achieved within ~7–10 days; contraceptive efficacy maintained with once-daily dosing.
Terminal elimination half-life is approximately 24-30 hours, supporting once-daily dosing in most patients.
Renal: ~60% (ethinyl estradiol metabolites as glucuronide/sulfate conjugates, norethindrone metabolites). Fecal: ~40% (biliary excretion of conjugates, with some enterohepatic recirculation).
Primarily renal (approximately 60-70% as metabolites, less than 10% as unchanged drug); fecal excretion accounts for about 20-30%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive